Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Multicenter, First-In-Human, Dose Escalation and Dose Expansion Study of CPO107 Administered Intravenously to Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

NCT04853329 is registered in ClinicalTrials.gov with Conjupro Biotherapeutics, Inc. as lead sponsor.

NCT NCT04853329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04853329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Multicenter, First-In-Human, Dose Escalation and Dose Expansion Study of CPO107 Administered Intravenously to Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
Lead sponsor
Conjupro Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 13, 2021
Completion date
January 31, 2023
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd20 positive non hodgkin lymphoma